Q-omics provides the consensus-scored SNX29P2 profile across patient tissues and cancer cell-line models. SNX29P2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SNX29P2 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, SNX29P2 RNA expression shows 13,364 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, THCA, and UVM as cancer lineages where SNX29P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX29P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX29P2 survival associations across molecular data types. SNX29P2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX29P2 RNA expression–survival associations across cancer types. High SNX29P2 expression shows unfavorable associations in UVM, LUSC, UCEC, LGG and ACC, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SNX29P2 RNA expression.
This table summarizes SNX29P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNX29P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX29P2 shows lower tumor expression in THCA, LUSC, ESCA and KIRP and higher tumor expression in HNSC and KICH. The THCA box plot shows higher SNX29P2 RNA expression in normal versus tumor tissue (log2 FC = −0.018, t-test p = .001).
This table shows molecular features associated with SNX29P2 in patient tissues and cancer cell lines. In patient samples, SNX29P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX29P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in NCI60_ALL.
